Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Upwork Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Upwork Inc trades at $8.44 (market cap $1.08B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 7× Upwork Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Upwork Inc for 38 Days on average.
| SYRE | UPWK | |
|---|---|---|
Market Cap | $7.52B | $1.08B |
Volume | 1,441,031 | 2,181,968 |
Sector | Health | Industrials |
52-Week High | $108.92 | $22.11 |
52-Week Low | $22.18 | $7.84 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $6.52B | $842.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
UPWK trades at $8.43, down 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though recent earnings showed two misses out of three quarters. Revenue growth has slowed from 28.02% in 2024 to 14.65% in 2025, with Q3 2026 earnings pending. Institutional buying interest exists with Bank of America acquiring 704,083 shares in September 2026.
UPWK presents a compelling value case with low P/E of 11.08 and P/S of 1.49, trading below the $9.64 consensus target. However, AI disruption to freelance markets and declining active client counts pose significant risks. The stock offers 14% upside to analyst targets but faces execution challenges amid industry transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
